Quality Segment
description
RTECS - YV7175000
assay
≥98% (TLC)
form
solid
manufacturer/tradename
Calbiochem®
storage condition
OK to freeze, desiccated (hygroscopic)
color
white
solubility
water: 20 mg/mL
shipped in
ambient
storage temp.
−20°C
SMILES string
[Cl-].N(CCOC(=O)C(CCC)(c2ccccc2)c1ccccc1)(CC)CC.[H+]
InChI
1S/C23H31NO2.ClH/c1-4-17-23(20-13-9-7-10-14-20,21-15-11-8-12-16-21)22(25)26-19-18-24(5-2)6-3;/h7-16H,4-6,17-19H2,1-3H3;1H
InChI key
FHIKZROVIDCMJA-UHFFFAOYSA-N
General description
Cell permeable. Blocks glibenclamide-sensitive K+ channels (IC50 = 4.4 µM). Inhibits neuronal nitric oxide synthase (IC50 = 90 µM). Also inhibits hepatic drug metabolism by inhibiting the cytochrome P-450 system. Stimulates endothelial cell prostocyclin production while inhibiting platelet thromboxane synthesis. Potentiates the effect of many drugs in vivo.
Biochem/physiol Actions
Cell permeable: yes
Primary Target
nNOS
nNOS
Product does not compete with ATP.
Reversible: no
Target IC50: 90 µM against neuronal nitric oxide synthase
Preparation Note
Following reconstitution, store in the refrigerator(4°C). Stock solutions are stable for up to 6 months at 4°C.
Other Notes
Hecker, M., et al. 1994. J. Neurochem. 62, 1524.
Sakuta, H. and Yoneda, I. 1994. Eur. J. Pharmacol.252, 117.
Khan, S., et al. 1993. Biochem. Pharmacol.45, 439.
Boeynaems, J.M., et al. 1986. Prostaglandins32, 145.
Lee, C.H., et al. 1976. J. Pharmacol. Exp. Ther.198, 347.
Grasdalen, J., et al. 1975. FEBS Lett.60, 240.
Sakuta, H. and Yoneda, I. 1994. Eur. J. Pharmacol.252, 117.
Khan, S., et al. 1993. Biochem. Pharmacol.45, 439.
Boeynaems, J.M., et al. 1986. Prostaglandins32, 145.
Lee, C.H., et al. 1976. J. Pharmacol. Exp. Ther.198, 347.
Grasdalen, J., et al. 1975. FEBS Lett.60, 240.
Legal Information
CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany
Disclaimer
Toxicity: Harmful (C)
存储类别
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable